At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Investigation of Safety and Efficacy of Five Doses of Semaglutide Versus Placebo and Open-label Liraglutide, as Add on Therapy, in Subjects Diagnosed With Type 2 Diabetes Currently Treated With Metformin or Controlled With Diet and Exercise A 12 Week Multi-centre, Multi National, Double-blind, Placebo-controlled, Randomised, Nine Armed Parallel Group, Dose Finding Trial
In Brief
A Phase 2 clinical trial evaluating semaglutide, placebo, and 1 other intervention for Diabetes and Diabetes Mellitus, Type 2. Completed, enrolled 415 participants across 77 sites in 14 countries.
Detailed Summary
This trial was conducted in Europe,Asia and Africa. Study participants were randomised evenly to treatment with semaglutide (0.1 mg QW - 1.6 mg QW, 6 treatment arms, placebo or liraglutide (1.2 mg QD, or 1.8 mg QD).Treatment allocation to semaglutide or placebo was double-blind, whereas liraglutide treatment was administered open-label.Primary efficacy parameter was HbA1c and the treatment duration was 12 weeks.
Study Details
Timeline
Interventions
0.1 mg, once weekly, s.c. injection
0.2 mg, once weekly, s.c. injection
0.4 mg, once weekly, s.c. injection
0.8 mg, once weekly, s.c. injection
0.8 mg with titration, once weekly, s.c. injection
1.6 mg with titration, once weekly, s.c. injection
0.1 mg, once weekly, s.c. injection
0.2 mg, once weekly, s.c. injection
0.4 mg, once weekly, s.c. injection
0.8 mg with titration, once weekly, s.c. injection
1.6 mg, once weekly, s.c. injection
1.2 mg with titration, once daily, s.c. injection
1.8 mg with titration, once daily, s.c. injection